1. Refers to an anti-EphA4 antibody or a part of union a EphA4, including: (a) cdr-h1, including the amino acid sequence represented by SEQ ID No: 26 or SEQ ID No: 27； (b) cdr-h2, including the amino acid sequence represented by SEQ ID No: 28 or SEQ ID No: 29； (c) CDR-H3, including the carbamate sequence represented by SEQ ID No. 30； (d) cdr-l1, including the carbamate sequence represented by SEQ ID No. 31； (E) cdr-l2, including the carbamate sequence represented by SEQ ID No. 32；(f) cdr-l3, including the amino acid sequence represented by SEQ ID No. 33. There, antibodies can be added to EphA4 and inhibited in EphA4 and its alliance. It also involves the determination of the determining region sequence for the complementarity of mouse anti-EphA4 antibody, and the preparation of a human antibody, including the CDR sequence of mouse anti-EphA4 antibody in high chain variable region and light chain variable region. It is used in the treatment of lateral aryl sclerosis (ELA).Referido a un anticuerpo anti-EphA4 o un fragmento de union a EphA4 del mismo, que comprende: a) CDR-H1 que comprende la secuencia de aminoacidos representada por SEQ ID NO: 26 o la SEQ ID NO: 27； b) CDR-H2 que comprende la secuencia de aminoacidos representada por SEQ ID NO: 28 o la SEQ ID NO: 29； c) CDR-H3 que comprende la secuencia de aminoacidos representada por SEQ ID NO: 30； d) CDR-L1 que comprende la secuencia de aminoacidos representada por SEQ ID NO: 31； e) CDR-L2 que comprende la secuencia de aminoacidos representada por SEQ ID NO: 32； y f) CDR-L3 que comprende la secuencia de aminoacidos representada por SEQ ID NO: 33. En donde dicho anticuerpo es capaz de unirse a EphA4 del mismo e inhibir la union entre EphA4 y su ligando. Tambien se refiere la identificacion de las secuencias de regiones determinantes de complementariedad (CDRs) del anticuerpo anti-EphA4 de raton, y a la preparacion de un anticuerpo humanizado que comprende las secuencias de CDR del anticuerpo antiEphA4 de raton en la
